BCAL Diagnostics Ltd
BCAL Diagnostics has a market price of 0.083 AUD and a market cap of 30,600,713.15 AUD, with a price-to-book ratio of 4.92 and a price-to-tangible-book ratio of 4.92. The company's enterprise value to EBITDA is -4.61, and its enterprise value to revenue is 11.63. The company's return on equity is -1.164, and its return on assets is -0.7308. The company's profitability is currently negative, with an operating income of -7,149,010 AUD and a net income of -7,241,040 AUD. The company's debt-to-equity ratio is 0.38, and its current ratio is 2.32, indicating moderate liquidity. BCAL Diagnostics generates revenue primarily from its non-invasive blood test, BREASTEST plus, which is used for breast cancer detection. The company's revenue is concentrated in this single product, with no disclosed geographic diversification. The company's growth trajectory is uncertain, with a negative operating cash flow of -6,135,890 AUD and a free cash flow of -7,026,760 AUD. The capital expenditure for the period is -787,680 AUD, indicating ongoing investment in operations. The company faces liquidity risks, with a negative net cash position after subtracting total debt. The risk of dilution is currently low, but the company's negative cash flows and high debt-to-equity ratio suggest potential future dilution risks. Recent financial filings indicate continued losses and negative cash flows, with no significant events disclosed in the period under review.
Business. BCAL Diagnostics Limited is an Australia-based biotechnology company focused on developing non-invasive blood screening tests for early and accurate breast cancer detection, with its primary product being the BREASTEST plus test.
Classification. BCAL Diagnostics is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.
- BCAL Diagnostics is a biotechnology company focused on breast cancer detection through non-invasive blood tests.
- The company is currently unprofitable, with significant negative operating and net income.
- The company's valuation metrics indicate a high price-to-book ratio and a negative enterprise value to EBITDA.
- The company's liquidity is moderate, with a current ratio of 2.32 and a debt-to-equity ratio of 0.38.
- The company's growth is constrained by negative cash flows and high capital expenditures.
- The company's risk profile includes liquidity risks and potential future dilution.
- # RATIONALES
- {
- Net cash is negative after subtracting total debt.